Moassefi, Mana

Abstract GBMs are highly aggressive tumors, evidenced by their rapid growth. Despite maximal treatment, median overall survival ranges between 16 and 20 months. Several studies use patients' diagnosis time(pre-surgical) imaging to predict their survival, but having a model that can predict the days till death for the patients who received the first standard step treatments (Stupp protocol) and now showing secondary progression signs is highly needed. In this study, we aimed to predict the overall survival of Glioblastoma(GBM) patients by developing a multimodal deep learning model using post-operative magnetic resonance imaging(MRI) and patients' age. We included GBM patients who met the following inclusion criteria: having maximum surgical resection followed by concurrent chemoradiation and showing secondary progression signs in follow-up imaging while being on adjuvant temozolomide treatment. We obtained contrast-enhanced T1(CET1) and T2-weighted(T2W) MRIs at progression time and patients' age and death dates. We calculated the days of survival from the day of the MRI. Dataset was split into train, validation, and test set at the patient level. CET1 and T2W MRIs were skull-stripped and coregistered for each patient. To mitigate data imbalance, we used the deep imbalance regression method for training a 3-D Densenet121 model with the concatenated CET1 and T2W as inputs. One hundred features were extracted from the optimized model and concatenated with the normalized age of each patient; the resulting output vectors were passed through the second dense neural network for final prediction. We included 110 patients who met the inclusion criteria. With the overall survival ranging from 16 to 4500 days, a mean of 582.4 and a standard deviation of 694.3, we achieved the test set's root mean square error of 261 days. Further refinement with more data, including clinical data such as comorbidities and external validation, is required prior to adoption in clinical practice.

Abstract INTRODUCTION Glioblastomas (GBMs) are highly aggressive tumors. A common clinical challenge after standard of care treatment is differentiating tumor progression from treatment-related changes, also known as pseudoprogression (PsP). Usually, PsP resolves or stabilizes without further treatment or a course of steroids, whereas true progression (TP) requires more aggressive management. Differentiating PsP from TP will affect the patient's outcome. This study investigated using deep learning to distinguish PsP MRI features from progressive disease. METHOD We included newly diagnosed GBM patients who met the inclusion criteria, including a new or increasing enhancing lesion size within the original radiation field and who had clinical, medication, and any histopathology available. The interpretation of the MR images at the image inclusion time point had to be indeterminate. We labeled those who subsequently were stable or improved on imaging and clinically as PSP and those with clinical and imaging deterioration as TP. A subset of subjects underwent a second resection. We labeled these subjects as PSP or TP based on the histological diagnosis. We performed skull stripping, coregistered contrast-enhanced T1 MRIs with T2-weighted images for each patient and used them as input to a 3-D Densenet121 model. We used several augmentation techniques and five-fold cross-validation to achieve more robust predictions. RESULT We included 124 patients who met the criteria, and of those, 63 were PsP and 61 were TP. We trained a deep learning model that achieved 76.4% (ranged 70%-84%, SD 5.122) mean accuracy over the 5 folds, 0.7560(ranged 0.6553-0.8535, SD 0.069) mean AUROCC, 88.72% (SD 6.86) mean sensitivity, and 62.05%(SD 9.11) mean specificity. CONCLUSION We report the development of a deep learning model that distinguishes PsP from TP in GBM patients treated per the Stupp protocol. Further refinement and external validation are required prior to widespread adoption in clinical practice.

Abstract PURPOSE Though patients with glioblastoma generally have poor overall survival (OS), OS estimates range significantly. We sought to develop a radiomics-based model predictive of OS in glioblastoma using preoperative MRI scans to identify these differences and guide clinical care. METHODS The primary endpoint was OS, determined from the date of surgery to death or last follow-up. T1, FLAIR, T2, and post-contrast T1 (T1c) MRI sequences were obtained for all patients. Using HD-GLIO-AUTO, lesion segmentation yielded three masks corresponding to the regions of contrast enhancement, non-enhancement, and total volume. Radiomics features were extracted from each region from the T2 and T1c sequences independently (i.e. either from T2 or T1c) and in combination. Age at surgery and gender were also considered. The data was split into training (75%) and test (25%) sets, stratifying for age at surgery. Kaplan-Meier analysis and the Coxnet model were used. For Coxnet, Elastic Net was used as the penalty, with optimization of the L1 coefficient using 5-fold cross-validation and evaluation via the concordance index (C-index). RESULTS From 3 institutions, 383 patients were included. Median OS was 395 days: 346 patients died, and 37 were right-censored. Age > 65 years was predictive of decreased OS (p < 0.005), but gender was not (p=0.16). For the Coxnet model, the C-index was 0.67 (standard deviation: 0.01) considering T2 and T1c sequences for the total lesion volume, with a C-index of 0.65 for the test set. For the enhancing volume, the model had a C-index of 0.71 for the test set using T1c sequences. Overall, C-indices ranged from 0.62-0.71. CONCLUSIONS We present a novel radiomics-based model predictive of OS in glioblastoma across a multi-institutional dataset. Ongoing efforts will incorporate immediate postoperative imaging and IDH and MGMT status into the proposed model to further improve prognostic ability and help guide clinical decision-making.

Machine-learning (ML) and deep-learning (DL) algorithms are part of a group of modeling algorithms that grasp the hidden patterns in data based on a training process, enabling them to extract complex information from the input data. In the past decade, these algorithms have been increasingly used for image processing, specifically in the medical domain. Cardiothoracic imaging is one of the early adopters of ML/DL research, and the COVID-19 pandemic resulted in more research focus on the feasibility and applications of ML/DL in cardiothoracic imaging. In this scoping review, we systematically searched available peer-reviewed medical literature on cardiothoracic imaging and quantitatively extracted key data elements in order to get a big picture of how ML/DL have been used in the rapidly evolving cardiothoracic imaging field. During this report, we provide insights on different applications of ML/DL and some nuances pertaining to this specific field of research. Finally, we provide general suggestions on how researchers can make their research more than just a proof-of-concept and move toward clinical adoption.

Abstract INTRODUCTION Glioblastomas (GBMs) are highly aggressive tumors. Despite multimodal treatment, its median overall survival ranges between 16 and 20 months. The standard treatment regimen consists of surgical resection followed by concurrent chemoradiotherapy and adjuvant temozolomide. Despite temozolomide’s effectiveness, it may cause the clinical challenge of treatment-related progression also known as pseudoprogression(PsP). Usually, PSP resolves or stabilizes without further treatment, whereas a true progression (TP) requires more aggressive management. Identifying PSP from TP will affect the patient’s treatment plan. Conventional magnetic resonance imaging (MRI) reading techniques cannot distinguish these entities. This study investigated the feasibility of using deep learning to distinguish PsP from TP. METHOD We included GBM patients who met our inclusion criteria. We evaluated all cases to see if they had a new enhancing lesion within the original radiation field or an increase in the size of an existing lesion. The challenging MRIs were collected. Clinical notes regarding tumor and recurrence location, clinical history, and medication were collected. We labeled the ones who stayed stable or improved in the imaging and clinical situation as PSP and those with further imaging and clinical deterioration as TP. We coregistered Contrast-enhanced-T1 MRIs with T2-weighted images for each patient. We performed five-fold cross-validation to generalize the performance. We trained A 3-D Densenet121 model to establish the prediction. We selected the best models with the highest accuracy. RESULT After reviewing 1000 patients, we included 124 patients whose imaging showed suspicious progression and their medicational histories were completely retrievable; 63 PsP, and 61 TP. We developed a deep learning model based on the whole dataset. The 5-fold cross-validation revealed that the mean area under the curve (AUC) was 0.81. CONCLUSION We report the development of a deep learning model that diagnoses PsP from TP in patients who received temozolomide. Further refinement and external validation are required prior to widespread adoption in clinical practice.